CP-IVX001: This study is looking into the safety and effectiveness of a new drug (IVX037) in people with advanced bowel, stomach, oesophagus or ovarian cancerA Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Exclusion

1. Candidate for hepatic surgery or locoregional therapy for liver lesions with curative intent or requires other systemic anti-cancer therapy.
2. Clinically significant ascites (Grade ≥2).
3. Other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subject to cooperate and participate in the trial; other examples of such conditions would include unstable or uncontrolled hypertension, unstable angina, myocardial infarction (MI) or cerebrovascular accident (CVA) within 6 months of study entry.
4. Requires continuous systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 4 weeks prior to the first dose of study treatment should be an EC.
5. Has not fully recovered from any effects of major surgery without significant detectable infection.
6. Bleeding diathesis due to underlying medical conditions or the use of anticoagulation medications that is unable to be reversed by medical treatment.

7. Tumors that lie close to an airway, major blood vessel or spinal cord, which, in the opinion of the Investigator, could cause occlusion, compression, or erosion of the vital structures.

   Prior/Concomitant Therapy

8. Participants who have been previously treated with an immune checkpoint inhibitor must have completed their last dose at least 21 days prior to Day 1, as long as there is demonstrated progressive disease during, or following the immune checkpoint inhibitor therapy.

9. Participants who require prohibited treatments (i.e., non-protocol-specified anticancer pharmacotherapy, surgery, or radiotherapy for treatment of malignancy).

   Prior/Concurrent Clinical Study Experience

10. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

11. Participants who have received a live or inactivated vaccine within 4 weeks of the first day of planned IVX037 treatment.

    Diagnostic Assessments

12. Participant with active (i.e., symptomatic or growing) CNS metastases. .
13. Participant has a known history of HIV
14. Active infection requiring systemic therapy.
15. Known additional malignancy that is progressing or requires active treatment.

16. A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

    Other Exclusions

17. Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the Screening visit through 120 days after the last dose of trial treatment.